A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Lung Cancer, Colorectal Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2011 |
| End Date: | June 2014 |
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study is to evaluate the safety and tolerability of escalating doses of
the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
This study is a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab
plus irinotecan. The study will assess the safety, tolerability, and pharmacokinetics of
MM-121, cetuximab and irinotecan.
plus irinotecan. The study will assess the safety, tolerability, and pharmacokinetics of
MM-121, cetuximab and irinotecan.
Inclusion Criteria:
- No standard options remaining
- Adequate liver and kidney functions
- 18 years of age or above
Exclusion Criteria:
- History of any secondary active cancer in the last 3 years.
- Pregnant or breast feeding
- History of severe allergic reactions or contraindications to cetuximab or irinotecan
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials